Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
BACKGROUND
Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ). Radiation is delivered up to a total dose of 60 Gy using photons. Using this treatment regimen, overall survival could be extended significantly however, median overall survival is still only about 15 months. Carbon ions offer physical and biological advantages. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increase relative biological effectiveness (RBE), which can be calculated between 2 and 5 depending on the GBM cell line as well as the endpoint analyzed. Protons, however, offer an RBE which is comparable to photons. First Japanese Data on the evaluation of carbon ion radiation therapy showed promising results in a small and heterogeneous patient collective.


METHODS
In the current Phase II-CLEOPATRA-Study a carbon ion boost will be compared to a proton boost applied to the macroscopic tumor after surgery at primary diagnosis in patients with GBM applied after standard radiochemotherapy with TMZ up to 50 Gy. In the experimental arm, a carbon ion boost will be applied to the macroscopic tumor up to a total dose of 18 Gy E in 6 fractions at a single dose of 3 Gy E. In the standard arm, a proton boost will be applied up to a total dose 10 Gy E in 5 single fractions of 2 Gy E. Primary endpoint is overall survival, secondary objectives are progression-free survival, toxicity and safety.


CONCLUSIONS
The Cleopatra Trial is the first study to evaluate the effect of carbon ion radiotherapy within multimodality treatment of primary glioblastoma in a randomized trial comparing this innovative treatment of the treatment standard, consisitng of photon radiotherapy in combination with temozolomide.


BACKGROUND
ISRCTN37428883 and NCT01165671.
Combs
Stephanie E
SE
Department of Radiation Oncology, University Hospital of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. stephanie.combs@med.uni-heidelberg.de
Kieser
Meinhard
M
Rieken
Stefan
S
Habermehl
Daniel
D
Jäkel
Oliver
O
Haberer
Thomas
T
Nikoghosyan
Anna
A
Haselmann
Renate
R
Unterberg
Andreas
A
Wick
Wolfgang
W
Debus
Jürgen
J
D000293:Adolescent; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000473:pathology / Q000628:therapy*; D002244:Carbon / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005909:Glioblastoma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D011379:Prognosis; D061766:Proton Therapy; D011879:Radiotherapy Dosage; D012062:Relative Biological Effectiveness; D015996:Survival Rate; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D002244:Carbon; D003606:Dacarbazine; D000077204:Temozolomide
Radiother Oncol. 2008 Feb;86(2):148-53
18237800
Biometrics. 1983 Jun;39(2):499-503
6354290
J Clin Oncol. 2002 Mar 15;20(6):1635-42
11896114
Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):407-21
12023146
J Neurosurg. 1999 Aug;91(2):251-60
10433313
Biometrics. 1979 Sep;35(3):549-56
497341
Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):803-8
11395250
J Clin Oncol. 2006 Jun 1;24(16):2563-9
16735709
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):449-57
17363188
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):171-7
17056193
Cancer. 2005 Jul 15;104(2):338-44
15937907
Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31
231022
J Clin Oncol. 2007 Mar 10;25(8):953-64
17350944
Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):390-6
17459607
Lancet Oncol. 2009 May;10(5):459-66
19269895
J Clin Oncol. 2005 Dec 1;23(34):8863-9
16314646
Radiother Oncol. 2010 Apr;95(1):54-9
20189258
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
2032882
Int J Radiat Biol. 2009 Feb;85(2):126-37
19280465
J Radiat Res. 2007 Jul;48(4):317-25
17548940
Cancer. 2009 Mar 15;115(6):1348-55
19156905